Clinical Trial Update: A Bioequivalence Study of APX001 High-load and Low-load Tablets [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing high-load and low-load APX001 tablets for invasive fungal infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Fungal Infection

Drugs mentioned

• APX001 (fosmanogepix)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Invasive Fungal Infections | Phase 1 | Status: COMPLETED